echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > The Synthetic Routes of Nelarabine

    The Synthetic Routes of Nelarabine

    • Last Update: 2023-05-01
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Nelarabine is a synthetic compound that is widely used in the pharmaceutical industry for the treatment of cancer.
    It is a nucleoside analogue that is specifically used for the treatment of T-cell lymphoma, a type of blood cancer that affects the immune system.
    The synthetic route of nelarabine is a complex and multistep process that involves the synthesis of several intermediate compounds.
    In this article, we will discuss the synthetic routes of nelarabine in detail.


    Step 1: The synthesis of 2,6-diaminopurine
    The synthesis of nelarabine begins with the synthesis of 2,6-diaminopurine, which is an intermediate compound in the production of nelarabine.
    This compound can be synthesized through several different routes, including the N-Boc saltylization of 2,6-diaminopyridine, the N-Boc aldol condensation of ethyl 3-dimethylaminopropionate, and the Suzuki reaction of 2-((S)-2-(diplopterylamino)indan-1-yl)acetic acid with boronic acid.


    Step 2: The synthesis of 5-oxoprolinyl ovaride
    The next step in the synthesis of nelarabine is the synthesis of 5-oxoprolinyl ovaride, which is another intermediate compound.
    This compound can be synthesized through several different routes, including the Williamson ether synthesis of 4-methoxy-2-oxopropanamide, the Prenzel reaction of 3-methyl-2-oxo-1,2-oxazolidine-4-carboxylic acid with 2-chloromethyl-3-oxo-1,2,3,4-tetrahydro-pyrrole-1-ium iodide, and the anti-Claisen condensation of 2-chloromethyl-3-oxo-1,2,3,4-tetrahydro-pyrrole-1-ium iodide with 5-formyl-2-oxoprolinamide.


    Step 3: The synthesis of N-hydroxy-2,2-dimethyl-4-oxo-1,3,2,4-tetrahydro-pirimidine-5-amide
    The synthesis of N-hydroxy-2,2-dimethyl-4-oxo-1,3,2,4-tetrahydro-pirimidine-5-amide is the next step in the synthesis of nelarabine.
    This compound can be synthesized through several different routes, including the Pechmann condensation of 2,2-dimethyl-4-oxo-1,3,2,4-tetrahydro-pirimidine-5-amide with benzaldehyde, the Bischler-Napieralski reaction of 2-chloromethyl-5-hydroxymethyl-2,3-oxazepanone with 2-hydroxy-2,3-dimethyl-4-oxo-1,3,2,4-tetrahydro-pirimidine, and the reduction of 2,2-dimethyl-4-oxo-1,3,2,4-tetrahydro-pirimidine-5-carbaldehyde with lithium aluminum hydride.


    Step 4: The synthesis of 2-chloromethyl-3-oxo-1,2,3,4-tetrahydro-p yrrole-1-ium iodide
    The synthesis of 2-chloromethyl-3-oxo-1,2,3,4-tetrahydro-p yrrole-1-ium iodide is the next step in the synthesis of nelarabine.
    This compound can be synthesized through several different routes, including the Swern oxidation of 3-hydroxy-2-butanone, the halogenation of 3-methyl-2-oxo-1,2,3,4-tetrahydro-p yrrole with bromine, and the halogenation of 3-methyl-2-oxo-1,2,3,4-tetrahydro-


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.